Journals / Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi / 2017 / Cilt: 14 - Sayı: 3

Pharmacotherapy For Stress Urinary Incontinence In Women

Kadınlarda Stres Üriner İnkontinansın Farmakolojik Tedavisi

Pages
127–132
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the features of duloxetine therapy together with the other agents and the important aspect to be considered are discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Urinary incontinence is a widespread debilitating and distressing condition in women and generally under-reported and undertreated.
📊
Key Findings & Data:Stress urinary incontinence SUI is the most common type of incontinence.This condition is associated with social isolation, psychological impairement, restriction of physical activities and sexual dysfunction.
💡
Conclusion & Impact:In this review, the features of duloxetine therapy together with the other agents and the important aspect to be considered are discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Stres üriner inkontinans · farmakoterapi · duloksetin

Abstract

Urinary incontinence is a widespread debilitating and distressing condition in women and generally under-reported and undertreated. Stress urinary incontinence SUI is the most common type of incontinence.This condition is associated with social isolation, psychological impairement, restriction of physical activities and sexual dysfunction. Treatment options for SUI include conservative, medical treatment and surgery.Treatment of SUI should be individualized.Pharmacotherapy may be alternative options in womenwho do not wish to undergo a surgery or whose the surgery is contraindicated. Various drugs, including alpha receptor agonists, beta receptor antagonists, serotonin-adrenaline re-uptake inhibitors, and estrogen have been used. Among these agents, duloxetine is the only drug that has obtained approval for the treatment of SUI. In this review, the features of duloxetine therapy together with the other agents and the important aspect to be considered are discussed.

Özet

Üriner inkontinans kadınları zayıflatan ve sıkıntıya sokan yaygın bir durumdur ve genellikle rapor edilmez ve tedavi edilmezler. Stres üriner inkontinans SÜİ en yaygın inkontinans tipini oluşturmaktadır. SÜİ yüksek prevalansı ve yaşam kalitesine olumsuz etkileri nedeniyle önemini korumakta olan bir hastalıktır. Bu durum sosyal izolasyon, psikolojik rahatsızlık, fiziksel aktivitelerden kaçınma ve seksüel disfonksiyonla ilişkilidir. SÜİ’nin tedavisinde konservatif, medikal tedavi ve cerrahi yer almaktadır. Stres üriner inkontinansın tedavisi bireyselleştirilmelidir. Medikal tedavi, cerrahi olmak istemeyen ya da cerrahinin kontraendike olduğu kadınlarda alternatif bir seçenek olabilir. Ameliyat olamayan ya da ameliyatı istemeyen hastalar için de cerrahi dışı yöntemler bir seçenek olabilmektedir. Cerrahi dışı tedavi seçeneklerinden birisi de farmakoterapidir. Alfa reseptör agonitleri, beta reseptör agonistleri, beta reseptör antagonistleri, trisiklik antidepresanlar, antikolinerjikler, serotonin-adrenalin geri alım inhibitörleri ve östrojenleri içeren çeşitli ilaçlar kullanılmaktadır. Bu ilaçlar içerisinde SÜİ tedavisi için onay alan tek ilaç duloksetindir. Bu derlemede diğer ajanlarla birlikte duloksetin tedavisinin özellikleri ve dikkat edilmesi gereken noktalar ele alınmıştır.

🔖

Cite This Article

AKSAKAL, O. S., EVLİYAOĞLU, Ö., ÇELİK, H. K., KARAKAYA, B. K. (2022). Pharmacotherapy For Stress Urinary Incontinence In Women. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, Cilt: 14 - Sayı: 3, 127–132. https://ajindex.com/articles/558743

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al.; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003 Jan;61(1):37-49
  2. Oh SJ, Ku JH, Choo MS, Yun JM, Kim DY, Park WH. Health-related quality of life and sexual function in women with stress urinary incontinence and overactive bladder. Int J Urol. 2008 Jan;15(1):62-7
  3. Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary in- continence in women in four European countries. BJU Int. 2004 Feb;93(3):324-30 DeLancey JOL. The pathophysiology of stres urinary incontinence in women and its implications for surgical treatment. World J Urol. 1997;15(5):268-274
  4. Hilton P, Stanton SL. Urethral pressure measurement by microtransdu- cer: the results in symptom-free women and in those with genuine stress incontinence. Br J Obstet Gynaecol. 1983 Oct;90(10):919-33
  5. Malallah MA, Al-Shaiji TF. Pharmacological treatment of pure stress urinary incontinence: a narrative review. Int Urogynecol J. 2015 Apr;26(4):477-85.
  6. Brune ME, O’Neill AB, Gauvin DM, Katwala SP, Altenbach RJ, Brioni JD, et al. Comparison of alpha 1-adrenoceptor agonists in canine urethral pressure profilometry and abdominal leak point pressure models. J Urol. 2001 Oct;166(4):1555-9
  7. Diokno AC, Taub M. Ephedrine in treatment of urinary incontinence. Uro- logy. 1975 May;5(5):624-5
  8. Collste L, Lindskog M. Phenylpropanolamine in treatment of female stress urinary incontinence. Double-blind placebo controlled study in 24 patients. Urology. 1987 Oct;30(4):398-403. Agency for Healthcare Policy and Research. Urinary Incontinence Gui- deline Panel. Urinary Incontinence in Adults: Clinical Practice Guideline (AHCPR publication #92-0038).
  9. Rockville, MD, US Dept. of Health and Human Services, 1992.
  10. Alhasso A, Glazener CM, Pickard R, N’dow J. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001842 Radley SC, Chapple CR, Bryan NP, Clarke DE, Craig DA.Effect of met- hoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study. Neurourol Urodyn 2001;20(1):43. Weil EH, Eerdmans PH, Dijkman GA, Tamussino K, Feyereisl J, Vierhout ME, et al. Randomized doubleblind placebo controlled multicenter evalu- ation of efficacy and dose finding of midodrine hydr